Physician profile
Islam Hussein
NPI 1821612185
$1,835.52
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.83 · 2021: $23.88 · 2022: $450 · 2023: $1,011 · 2024: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $278.42 | 2020-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $262.74 | 2022-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.06 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $206.14 | 2022-2023 | Hetlioz, Fanapt |
| Abbvie INC. | $147.58 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $124.58 | 2022-2023 | Nuedexta, Abilify Maintena |
| Indivior INC. | $120.16 | 2022-2023 | Perseris |
| Alkermes, INC. | $114.77 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $112.02 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $101.03 | 2024 | Uzedy |
| Lundbeck LLC | $38.29 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $32.10 | 2022 | |
| Noven Therapeutics, LLC | $29.23 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.40 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Islam Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.